Audentes Therapeutics (BOLD) started trading on the Nasdaq on 19 July 16

• Headquarters: San Francisco, CA
• Founded: 2012
• audentestx.com

Audentes is one of the leaders in the nascent field of gene therapy, using an adeno-associated virus, or AAV, vector to carry a healthy copy of a gene into a cell. The viral vectors essentially are vehicles, modified so they aren't infectious but can slip past a cell's normal defenses to deliver the healthy gene.

Audentes sold 5 million shares at $15 apiece in its IPO. The $75 million raise will help Audentes fund clinical work it’s doing on rare diseases such as X-Linked myotubular myopathy, Crigler-Najjar Syndrome, and Pompe disease.

Description

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Key stats and ratios

	Q2 (Jun '17)	2016
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-58.78%	-45.98%
Return on average equity	-68.94%	-139.89%
Employees	97

Amplify Snack Brands (BETR) reported Q3 earnings on Mon 14 November 2016

** charts after earnings **

** 3 days later **

AUSTIN, Texas (AP) _ Amplify Snack Brands Inc. (BETR) on Monday reported third-quarter net income of $1.6 million, after reporting a loss in the same period a year earlier.

The Austin, Texas-based company said it had profit of 2 cents per share. Earnings, adjusted for non-recurring costs, were 12 cents per share.

The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 15 cents per share.

The popcorn and tortilla chip maker posted revenue of $68 million in the period, beating Street forecasts. Five analysts surveyed by Zacks expected $64.7 million.

Amplify expects full-year earnings in the range of 49 cents to 51 cents per share, with revenue in the range of $268 million to $272 million.

Amplify shares have increased 17 percent since the beginning of the year. In the final minutes of trading on Monday, shares hit $13.47, a rise of 11 percent in the last 12 months.

Mindbody (MB) reported earnings on Wed 26 Oct 2016 (a/h)

Ticker: MB

** charts after earnings **

 

SAN LUIS OBISPO, Calif. (AP) _ Mindbody Inc. (MB) on Wednesday reported a loss of $5.9 million in its third quarter.

On a per-share basis, the San Luis Obispo, California-based company said it had a loss of 15 cents. Losses, adjusted for stock option expense, were 9 cents per share.

The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share.

The business management software developer posted revenue of $35.3 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $35 million.

For the current quarter ending in December, Mindbody said it expects revenue in the range of $37.7 million to $38.7 million.

The company expects full-year revenue in the range of $138.5 million to $139.5 million.

Mindbody shares have risen 18 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $17.90, a climb of 11 percent in the last 12 months.

Goldman Sachs MLP (GMZ) : 1-year performance

** daily **

** weekly **

Amphastar Pharmaceuticals (AMPH) began trading on the NASDAQ on 25 June 2014

Description

Amphastar Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products. The Company’s generic product candidates at various development stages that leverage its various technical capabilities, including injectable technologies, including various delivery methods and sizes of pre-filled syringes, vials in solution, suspension and lyophilized forms; inhalation technologies, including metered dose inhalers (MDIs) and metered dose inhalers (DPIs); and analytical technologies. As of May 20, 2014, the Company manufactures and sells 15 products in the United States and is developing a portfolio of 13 generic and seven injectable and inhalation product candidates. In addition to its marketed products, it has a pipeline of 20 generic and product candidates in various stages of development which target a variety of indications.

Address

11570 6th St
RANCHO CUCAMONGA, CA 91730-6025
United States

Website 

http://www.amphastar.com

Key stats and ratios

	Q2 (Jun '14)	2013
Net profit margin	-2.41%	5.16%
Operating margin	-2.39%	7.61%
EBITD margin	-	13.36%
Return on average assets	-1.28%	3.55%
Return on average equity	-1.76%	4.89%
Employees	1,217

Noodles & Co (NDLS) : 14-month performance

** daily **

** weekly **

The trading disaster that is Noodles & Co. (NDLS) was holding to form early Thursday, plunging 21% after another weaker-than-expected quarterly report delivered further misery to anyone owning the shares.

Following its fourth consecutive quarterly sales shortfall and a reduced outlook for the full year, the stock was losing $5.24 to $19.97, its lowest price since it started trading 14 months ago.

Investors had viewed Noodles' debut as that of a restaurant with the opportunity -- possibly -- to be "the next Chipotle." Instead, they've gotten little but distress if they've been with the name for any time aside from brief, fortunate upward spurts. The stock opened for trading at $32 after its June 2013 IPO, rising to $51.97 days later. It's been stepping lower since, but the current decline would be the worst trading day it's had. Previously, its largest single-day drop was a 13.7% fall on April 30, after disappointing first-quarter earnings.

Even before the latest decrease, shares were down 29.4% in 2014. At this point, they're 61% below their peak.

For the second quarter, revenue did climb 11.5% from the year-earlier period to $99.5 million, the Broomfield, Colo.-based noodle seller said. However, analysts were expecting $103.3 million, according to FactSet. In the five quarters Noodles has reported as a public company, it only surpassed revenue estimates the first time. Meanwhile, adjusted earnings of 12 cents a share missed the consensus of 15 cents and were down a penny from last year. Same-store sales fell 0.6% at company-owned restaurants.

Noodles has now opened 25 company stores through the first half, compared with a goal of 45 to 50 for the entire year, so it says the high end is within reason. Also, five franchised locations have opened. The company has said it believes it can eventually have 2,500 stores, up from 410 operating today, most of which are corporate-owned.

Zafgen (ZFGN) began trading on the NASDAQ on 19 June 2014

Zafgen (ZFGN), a biotech developing a treatment for severe obesity and hunger-related disorders

Offered 5.0 million shares 

Zafgen was founded in 2005 in Cambridge, MA. 

Leerink Partners and Cowen & Company are the joint bookrunners on the deal.

Description

Zafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity. Beloranib, the Company’s product candidate, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome (PWS), craniopharyngioma-associated obesity, and severe obesity in the general population. PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms, including hyperphagia and obesity. Craniopharyngioma is a rare form of benign brain tumor that occurs near the optic nerve, pituitary gland and hypothalamus. Approximately 30% to 50% of cases of craniopharyngioma are diagnosed in childhood and adolescence.

Address

8TH FLOOR, ONE BROADWAY
CAMBRIDGE, MA 02142
United States 

Key stats and ratios

	Q1 (Mar '14)	2013
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-45.00%	-57.11%
Return on average equity	-	-
Employees	10

Century Communities (CCS) began trading on the NYSE on 18 June 2014

Century Communities, Inc. is engaged in homebuilding activities primarily in metropolitan markets in Colorado. Its activities comprise land acquisition, development, and entitlements; and the acquisition, development, construction, marketing, and sale of various single-family detached and attached residential home projects. The company also operates in the greater Austin and San Antonio, Texas and Las Vegas, and Nevada metropolitan areas. As of April 1, 2014, it owned and controlled approximately 99 communities consisted of 10,095 lots. Century Communities, Inc. was founded in 2000 and is based in Greenwood Village, Colorado.

Century Communities booked $287 million in sales over the last 12 months.  FBR Capital Markets, J.P. Morgan and Deutsche Bank are the joint bookrunners on the deal.

CST Brands (CST) : 14-month performance

Ticker:  CST